Abstract
Background: The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods: We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$ per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings: In 2019, health spending globally reached $8·8 trillion (95% uncertainty interval [UI] 8·7–8·8) or $1132 (1119–1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total, $40·4 billion (0·5%, 95% UI 0·5–0·5) was development assistance for health provided to low-income and middle-income countries, which made up 24·6% (UI 24·0–25·1) of total spending in low-income countries. We estimate that $54·8 billion in development assistance for health was disbursed in 2020. Of this, $13·7 billion was targeted toward the COVID-19 health response. $12·3 billion was newly committed and $1·4 billion was repurposed from existing health projects. $3·1 billion (22·4%) of the funds focused on country-level coordination and $2·4 billion (17·9%) was for supply chain and logistics. Only $714·4 million (7·7%) of COVID-19 development assistance for health went to Latin America, despite this region reporting 34·3% of total recorded COVID-19 deaths in low-income or middle-income countries in 2020. Spending on health is expected to rise to $1519 (1448–1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation: Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Funding: Bill & Melinda Gates Foundation.
Original language | English (US) |
---|---|
Pages (from-to) | 1317-1343 |
Number of pages | 27 |
Journal | The Lancet |
Volume | 398 |
Issue number | 10308 |
DOIs | |
State | Published - Oct 9 2021 |
Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: The Lancet, Vol. 398, No. 10308, 09.10.2021, p. 1317-1343.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Tracking development assistance for health and for COVID-19
T2 - a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050
AU - Global Burden of Disease 2020 Health Financing Collaborator Network
AU - Micah, Angela E.
AU - Cogswell, Ian E.
AU - Cunningham, Brandon
AU - Ezoe, Satoshi
AU - Harle, Anton C.
AU - Maddison, Emilie R.
AU - McCracken, Darrah
AU - Nomura, Shuhei
AU - Simpson, Kyle E.
AU - Stutzman, Hayley N.
AU - Tsakalos, Golsum
AU - Wallace, Lindsey E.
AU - Zhao, Yingxi
AU - Zende, Rahul R.
AU - Abbafati, Cristiana
AU - Abdelmasseh, Michael
AU - Abedi, Aidin
AU - Abegaz, Kedir Hussein
AU - Abhilash, E. S.
AU - Abolhassani, Hassan
AU - Abrigo, Michael R.M.
AU - Adhikari, Tara Ballav
AU - Afzal, Saira
AU - Ahinkorah, Bright Opoku
AU - Ahmadi, Sepideh
AU - Ahmed, Haroon
AU - Ahmed, Muktar Beshir
AU - Ahmed Rashid, Tarik
AU - Ajami, Marjan
AU - Aji, Budi
AU - Akalu, Yonas
AU - Akunna, Chisom Joyqueenet
AU - Al Hamad, Hanadi
AU - Alam, Khurshid
AU - Alanezi, Fahad Mashhour
AU - Alanzi, Turki M.
AU - Alemayehu, Yosef
AU - Alhassan, Robert Kaba
AU - Alinia, Cyrus
AU - Aljunid, Syed Mohamed
AU - Almustanyir, Sami Almustanyir
AU - Alvis-Guzman, Nelson
AU - Alvis-Zakzuk, Nelson J.
AU - Amini, Saeed
AU - Amini-Rarani, Mostafa
AU - Amu, Hubert
AU - Ancuceanu, Robert
AU - Andrei, Catalina Liliana
AU - Berman, Adam E.
AU - Guha, Avirup
N1 - Funding Information: J L Dieleman reports support for the current manuscript from the Bill & Melinda Gates Foundation. This research was funded in part by the Wellcome Trust (grant number 220211). S Nomura acknowledges support from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). S Afzal acknowledges support from King Edward Medical University by facilitating qualified human resource to work on this research and complete it in a timely manner. S M Aljunid would like to acknowledge the Department of Health Policy and Management, Faculty of Public Health, Kuwait University; and International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia for the approval and support to participate in this research project. S Bhaskar acknowledges funding support from the NSW Ministry of Health. T W Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. J-W De Neve was supported by the Alexander von Humboldt Foundation. M Golechha acknowledges being a project lead of NITI Aayog, Government of India funded project “Impact of the National Health Mission on Governance, Health System, and Human Resources for Health” and being a project lead of a Department of Science and Technology-funded project on the development and implementation of Heat Action Plan in Indian Cities under the National Mission on Strategic Knowledge for Climate Change. V K Gupta acknowledges funding support from NHMRC Australia. S M S Islam is supported by the NHMRC and the National Heart Foundation of Australia. M Jakovljevic was co-funded through Grant OI 175014 of the Ministry of Education Science and Technological Development of the Republic of Serbia. Y J Kim was supported by the Research Management Centre, Xiamen University Malaysia (number XMUMRF/2020-C6/ITCM/0004). S L Koulmane Laxminarayana acknowledges institutional support provided by Manipal Academy of Higher Education. K Krishan is supported by the UGC Centre of Advanced Study (phase II), awarded to the Department of Anthropology, Panjab University, Chandigarh, India. L K D Le acknowledges support from the Alfred Deakin Postdoctoral Research Fellowship and funding from the NHMRC PREMISE. R J Maude is supported by a grant from the Research Council of Norway (285188). B R Nascimento was supported in part by CNPq (Bolsa de produtividade em pesquisa, 312382/2019-7), by the Edwards Lifesciences Foundation (Every Heartbeat Matters Program 2020) and by FAPEMIG (grant APQ-000627-20). M D Naimzada, N Otstavnov, and S S Otstavnov acknowledge the support by a grant from the Russian Science Foundation (project number 20-78-10157). J R Padubidri acknowledges the Manipal Academy of Higher Education, Manipal for their support in research publications. B Reshmi acknowledges Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, India. A M Samy acknowledges the support from the Fellowship of the Egyptian Fulbright Mission program. A Sheikh is supported by the Health Data Research UK BREATHE Hub. A Shetty acknowledges support from Manipal Academy of Higher Education, Manipal. Funding Information: J L Dieleman reports support for the current manuscript from the Bill & Melinda Gates Foundation. This research was funded in part by the Wellcome Trust (grant number 220211). S Nomura acknowledges support from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). S Afzal acknowledges support from King Edward Medical University by facilitating qualified human resource to work on this research and complete it in a timely manner. S M Aljunid would like to acknowledge the Department of Health Policy and Management, Faculty of Public Health, Kuwait University; and International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia for the approval and support to participate in this research project. S Bhaskar acknowledges funding support from the NSW Ministry of Health. T W Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. J-W De Neve was supported by the Alexander von Humboldt Foundation. M Golechha acknowledges being a project lead of NITI Aayog, Government of India funded project “Impact of the National Health Mission on Governance, Health System, and Human Resources for Health” and being a project lead of a Department of Science and Technology-funded project on the development and implementation of Heat Action Plan in Indian Cities under the National Mission on Strategic Knowledge for Climate Change. V K Gupta acknowledges funding support from NHMRC Australia. S M S Islam is supported by the NHMRC and the National Heart Foundation of Australia. M Jakovljevic was co-funded through Grant OI 175014 of the Ministry of Education Science and Technological Development of the Republic of Serbia. Y J Kim was supported by the Research Management Centre, Xiamen University Malaysia (number XMUMRF/2020-C6/ITCM/0004). S L Koulmane Laxminarayana acknowledges institutional support provided by Manipal Academy of Higher Education. K Krishan is supported by the UGC Centre of Advanced Study (phase II), awarded to the Department of Anthropology, Panjab University, Chandigarh, India. L K D Le acknowledges support from the Alfred Deakin Postdoctoral Research Fellowship and funding from the NHMRC PREMISE. R J Maude is supported by a grant from the Research Council of Norway (285188). B R Nascimento was supported in part by CNPq (Bolsa de produtividade em pesquisa, 312382/2019-7), by the Edwards Lifesciences Foundation (Every Heartbeat Matters Program 2020) and by FAPEMIG (grant APQ-000627-20). M D Naimzada, N Otstavnov, and S S Otstavnov acknowledge the support by a grant from the Russian Science Foundation (project number 20-78-10157). J R Padubidri acknowledges the Manipal Academy of Higher Education, Manipal for their support in research publications. B Reshmi acknowledges Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal, India. A M Samy acknowledges the support from the Fellowship of the Egyptian Fulbright Mission program. A Sheikh is supported by the Health Data Research UK BREATHE Hub. A Shetty acknowledges support from Manipal Academy of Higher Education, Manipal. Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations. Funding Information: D McCracken's position was supported in part through the Wellcome Trust, and by the Department of Health and Social Care using UK aid funding managed by the Fleming Fund. R Ancuceanu reports consulting fees from AbbVie and AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Sandoz, AbbVie, and Braun Medical; and support for attending meetings or travel from AbbVie and AstraZeneca, all outside the submitted work. M Ausloos and C Herteliu report grants or contracts from the Romanian National Authority for Scientific Research and Innovation (CNDS-UEFISCDI), project number PN-III-P4-ID-PCCF-2016-0084, outside the submitted work. C Herteliu reports grants or contracts from CNDS-UEFISCDI, project number PN-III-P2-2.1-SOL-2020-2-0351, outside the submitted work. S Bhaskar reports an unpaid leadership or fiduciary role in a board, society, committee or advocacy group, with the Rotary Club of Sydney Board of Directors, outside the submitted work. R Busse reports grants or contracts from Berlin University Alliance (COVID pre-exploration project), outside the submitted work. S M S Islam reports grants or contracts from National Health and Medical Research Council (NHMRC) and the National Heart Foundation of Australia, all outside the submitted work. K Krishan reports non-financial support from UGC Centre of Advanced Study phase II, Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. M J Postma reports grants or contacts from Merck Sharp & DDohme, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Novavax, Bayer, Bristol Myers Squibb, AstraZeneca, Sanofi, IQVIA, BioMerieux, WHO, EU, Seqirus, FIND, Antilope, DIKTI, LPDP, and Budi; consulting fees from Merk Sharp & Dohme, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Novavax, Quintiles, Bristol Myers Squibb, Astra Zeneca, Sanofi, Novartis, Pharmerit, IQVIA, and Seqirus; participation on a Data Safety Monitoring Board or Advisory Board to Asc Academics as Advisor; and stock or stock options in Health-Ecore and PAG, all outside the submitted work. M G Shrime reports grants or contracts from the Iris O'Brien Foundation; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Brightsight speakers; and leadership or fiduciary role in board, society, committee or advocacy group, paid or unpaid with Pharos Global Health Advisors as a board member. J A Singh reports consulting fees from Crealta/Horizon, Medisys, Fidia, Two labs, Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, UBM, Trio Health, Medscape, WebMD, and Practice Point communications, and the National Institutes of Health and the American College of Rheumatology; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Simply Speaking; support for attending meetings and travel from OMERACT; leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, with OMERACT as a member of the steering committee, with the US Food and Drug Administration Arthritis Advisory Committee, with the Veterans Affairs Rheumatology Field Advisory Committee as a member, and with the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis as a Director and Editor; stock or stock options in TPT Global Tech, Vaxart pharmaceuticals, and Charlotte's Web Holdings; and previously owned stock options in Amarin, Viking, and Moderna pharmaceuticals, all outside the submitted work. All other authors declare no competing interests. Funding Information: Figure 2A shows the main sources of development assistance for health in 2020. Most of the funding came from the USA, the UK, and the Bill & Melinda Gates Foundation. The key disbursing agencies for these resources were USA bilateral organisations, non-governmental organisations, and the World Bank ( figure 2B ). Publisher Copyright: © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2021/10/9
Y1 - 2021/10/9
N2 - Background: The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods: We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$ per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings: In 2019, health spending globally reached $8·8 trillion (95% uncertainty interval [UI] 8·7–8·8) or $1132 (1119–1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total, $40·4 billion (0·5%, 95% UI 0·5–0·5) was development assistance for health provided to low-income and middle-income countries, which made up 24·6% (UI 24·0–25·1) of total spending in low-income countries. We estimate that $54·8 billion in development assistance for health was disbursed in 2020. Of this, $13·7 billion was targeted toward the COVID-19 health response. $12·3 billion was newly committed and $1·4 billion was repurposed from existing health projects. $3·1 billion (22·4%) of the funds focused on country-level coordination and $2·4 billion (17·9%) was for supply chain and logistics. Only $714·4 million (7·7%) of COVID-19 development assistance for health went to Latin America, despite this region reporting 34·3% of total recorded COVID-19 deaths in low-income or middle-income countries in 2020. Spending on health is expected to rise to $1519 (1448–1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation: Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Funding: Bill & Melinda Gates Foundation.
AB - Background: The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods: We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$ per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings: In 2019, health spending globally reached $8·8 trillion (95% uncertainty interval [UI] 8·7–8·8) or $1132 (1119–1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total, $40·4 billion (0·5%, 95% UI 0·5–0·5) was development assistance for health provided to low-income and middle-income countries, which made up 24·6% (UI 24·0–25·1) of total spending in low-income countries. We estimate that $54·8 billion in development assistance for health was disbursed in 2020. Of this, $13·7 billion was targeted toward the COVID-19 health response. $12·3 billion was newly committed and $1·4 billion was repurposed from existing health projects. $3·1 billion (22·4%) of the funds focused on country-level coordination and $2·4 billion (17·9%) was for supply chain and logistics. Only $714·4 million (7·7%) of COVID-19 development assistance for health went to Latin America, despite this region reporting 34·3% of total recorded COVID-19 deaths in low-income or middle-income countries in 2020. Spending on health is expected to rise to $1519 (1448–1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation: Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Funding: Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85116527441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116527441&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)01258-7
DO - 10.1016/S0140-6736(21)01258-7
M3 - Article
C2 - 34562388
AN - SCOPUS:85116527441
SN - 0140-6736
VL - 398
SP - 1317
EP - 1343
JO - The Lancet
JF - The Lancet
IS - 10308
ER -